



05.05.05

DFW

Docket 17637 (BOT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: FIRST, ERIC R.

Serial No.: 10/731,973

Filed: December 9, 2003

For: BOTULINUM TOXIN THERAPY
FOR SKIN DISORDERS

Examiner:

Group Art Unit:

Irvine, California

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant provides with regard to the above-identified patent application entitled BOTULINUM TOXIN THERAPY FOR SKIN DISORDERS, one copy of documents of which he is aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of the documents submitted is set forth on the attached Information Disclosure Citation (Form PTO-1449).


While these documents may be material pursuant to 37 C.F.R. §1.56, the disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. These documents were disclosed in an International Search Report in the foreign counterpart of the above-identified application, and were received less than three (3) months ago. Please do not

hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date: May 2, 2005


Stephen Donovan
Attorney of Record
Registration Number 33,433

Please direct all inquiries and correspondence to:

Stephen Donovan
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: (714) 246-4026
Fax: (714) 246-4249

CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date May 3, 2005 in an envelope as "Express Mail Post Office to Addressee" Mailing Label number EL980001510US addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Adriane Giberson
Name of person mailing paper

Date May 3, 2005


Signature of person signing paper

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17637 (BOT)	SERIAL NO.: 10/731,973
APPLICANT: FIRST, ERIC R.	TITLE: BOTULINUM TOXIN THERAPY FOR SKIN DISORDERS
FILING DATE: December 9, 2003	GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	2001-0175400		Borodic	424	239.1	09/09/2004
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA	WO 00/24419	10/15/1999	PCT	A61K	39/08	Y
	BB	WO 03/011333	02/03/2003	PCT	A61K	39/10	Y

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	Gibbs, S., et al., <i>Review: common topical applications containing salicylic acid or lactic acid improve clinical cure in non-refractory viral warts</i> , downloaded from ebm.bmjournals.com, EBM Volume 8 March/April 2003, pg. 59
	CB	Swartling, C., et al, <i>Treatment of Dyshidrotic hand dermatitis with intradermal botulinum toxin</i> , Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 365, no. Supplement 2, June 2002 (2002-06), pg. R46
	CC	
	CD	
	CE	
	CF	
	CG	
	CH	

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.